Therapy Produced Positive Results For Outpatients With Mild and Uncomplicated COVID-19

California-based Eiger BioPharmaceuticals announced on September 28, 2020, results of an investigator-sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19. The study was co-led by Stanford University School of Medicine researchers Upinder Singh, M.D., and Prasanna Jagannathan, M.D., with the primary endpoint duration of viral shedding. The study's secondary endpoint was reducing the duration of symptoms and hospitalization in patients with mild COVID-19.

No difference was demonstrated in the duration of SARS-CoV-2 viral shedding and time to symptom resolution when compared with placebo. The median time to cessation of viral shedding in both study groups was 7-days. Lambda was found well-tolerated with few adverse events, which included elevated transaminases which self-resolved.